Adagrasib safe and clinically active in non-small cell lung cancer Presented ByDr Alexander Spira, Virginia Cancer Specialists Research Institute, VA, USA TrialPhase 2, KRYSTAL-1 ConferenceASCO 2022 5 August, 2022 12:33
Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC Presented ByDr Jared Weiss, University of North Carolina at Chapel Hill, NC, USA TrialPhase 1/2, KRYSTAL-1 ConferenceESMO 2021 19 November, 2021 09:42
